Mr Noal Baxter Cochran, MS, LMFT | |
80 Lakeland Circle, Petal, MS 39465 | |
(601) 297-1886 | |
Not Available |
Full Name | Mr Noal Baxter Cochran |
---|---|
Gender | Male |
Speciality | Marriage & Family Therapist |
Location | 80 Lakeland Circle, Petal, Mississippi |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1023228640 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | T0382 (Mississippi) | Primary |
106H00000X | Marriage & Family Therapist | MFT001031 (Georgia) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Mr Noal Baxter Cochran, MS, LMFT 80 Lakeland Circle, Petal, MS 39465 Ph: (601) 297-1886 | Mr Noal Baxter Cochran, MS, LMFT 80 Lakeland Circle, Petal, MS 39465 Ph: (601) 297-1886 |
News Archive
Treating patients with acute respiratory failure is a constant challenge in intensive care medicine. In most cases, the underlying cause is lung inflammation triggered by a bacterial infection or - more rarely, despite being frequently observed at present due to the corona pandemic - a viral infection.
A team of scientists from the United Kingdom has recently revealed the therapeutic benefits of histamine receptor antagonists in reducing long-term symptoms of coronavirus disease 2019 (COVID-19). They have also indicated that T cell immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection vary between asymptomatic COVID-19 and long-COVID.
Chronix Biomedical announced today that it filed a provisional United States patent application jointly with Hemispherx Biopharma, Inc. on a blood test for Chronic Fatigue Syndrome.
Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, today announced the results of a Phase 1 trial and preclinical data on its lead drug candidate ACHN-490 at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting in San Francisco, CA.
Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known as c-MET which is overexpressed in many cancers.
› Verified 8 days ago
Sharon D Adams, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 128 N Main St, Petal, MS 39465 Phone: 601-255-4240 |